BNP Therapy Observation Unit Outcomes STudy (BOOST)

Stopped early · Phase 4

Conditions studied: Congestive Heart Failure

In brief

The investigators hypothesize that patients admitted to an emergency department (ED) observation unit will have a decreased rate of hospital admissions and ED recidivism when treated with nesiritide versus standard therapy. The investigators also hypothesize that decreasing B-type Natriuretic Peptide (BNP) levels during treatment in an ED observation unit will predict improved patient outcomes.

Key facts

Study ID

NCT00453453

Run by

Emory University

People needed

17

Starts

2007-03-01

Expected to finish

2007-09-01

Last updated by the study team

2015-02-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patient > 18 years of age
• Have a working diagnosis of HF, as determined by the emergency physician using the Boston Criteria. A score of 8-12 is required for inclusion in the study.
• Alert, oriented and able to provide informed consent.
• Able to be contacted by telephone for follow up after discharge, and have none of the study exclusion criteria.

You may not qualify if…

• Dialysis Dependent Renal Failure
• Temperature > 38.5 degrees celsius
• Pneumonia (Infiltrates on Chest X-ray)
• Requiring IV vasoactive agents (Other than Nesiritide)
• Killip Class III/IV
• Systolic blood pressure < 90 mmHg
• EKG diagnostic or suggestive of Acute myocardial infarction or ischemia
• Abnormal Cardiac Markers
• Lack of a telephone
• Inability to provide informed consent due to cognitive impairment or a severe psychiatric disorder

Where it is running

• Grady Memorial Hosptial — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.